Angiogenesis and Drug Resistance in Breast Cancer
New Research Sheds Light on How Abnormal Blood Vessels Fuel Drug Resistance in Breast Cancer
Scientists pinpoint angiogenesis as a key driver of treatment failure and explore promising new strategies to overcome it.
Breast cancer remains a formidable foe, notorious for its ability to evade a wide range of treatments. from surgery and chemotherapy to targeted therapies and immunotherapy, the disease often develops resistance, leaving patients with limited options. Now, groundbreaking research from zhejiang Chinese Medical University is shedding light on a critical factor contributing to this resistance: angiogenesis.
Angiogenesis, the formation of new blood vessels, is a hallmark of cancer. While healthy tissues rely on a carefully regulated network of blood vessels,tumors hijack this process,sprouting a chaotic web of abnormal vessels. This seemingly innocuous process has dire consequences.
“These abnormal blood vessels not only worsen tumor oxygen deficiency (hypoxia) but also act as a barrier, preventing drugs from reaching their target,” explains Dr. Jiancheng Mou, lead investigator of the study. “This effectively shields the tumor from treatment, rendering many therapies ineffective.”
Published in Cancer Biology & Medicine, the review delves into the intricate relationship between angiogenesis and drug resistance in breast cancer.It highlights how anti-angiogenic therapies, designed to normalize these aberrant blood vessels, hold immense promise for overcoming this challenge.
The study explores various anti-angiogenic drugs, their mechanisms of action, and their potential to synergize with existing treatments like chemotherapy, targeted therapy, and immunotherapy. By disrupting the tumor’s blood supply and restoring normal blood flow, these therapies could pave the way for more effective drug delivery and improved treatment outcomes.
“Our findings demonstrate that angiogenesis is a central driver of drug resistance in breast cancer,” emphasizes Dr. Mou. “By targeting these abnormal blood vessels, we can enhance the potency of existing treatments, offering a more effective strategy to combat this devastating disease and ultimately improve patient survival.”
This research offers a glimmer of hope for the millions of women battling breast cancer. By incorporating anti-angiogenic therapies into treatment plans, clinicians might potentially be able to personalize treatment, reduce drug resistance, and ultimately improve survival rates and quality of life for patients worldwide.
Fighting Back: Can Targeting Blood Vessels Beat Drug Resistance in Breast Cancer?
NewsDirect3.com – Breast cancer treatment, while making strides, is ofen hampered by the frustrating problem of drug resistance. Tumors, cunningly evading therapies, leave patients with limited options. New research from Zhejiang Chinese Medical University shines a light on a key culprit behind this resistance: angiogenesis, the formation of new blood vessels.
This process, essential for healthy tissue development, goes awry in cancer. Tumors hijack angiogenesis, creating a chaotic web of abnormal blood vessels that act as both a shield and a suffocating blanket.
“These abnormal vessels worsen the oxygen deprivation (hypoxia) within the tumor, making it even more aggressive,” explains Dr. Jiancheng Mou, lead investigator of the study. “Worse yet, they act as barriers, preventing drugs from reaching their target and effectively protecting the cancer from treatment.”
Published in Cancer Biology & Medicine, Dr. MouS review examines the intricate link between angiogenesis and drug resistance. The research emphasizes the potential of anti-angiogenic therapies, designed to normalize these abnormal vessels, as a promising weapon against drug resistance.
These therapies aim to disrupt the tumor’s blood supply, restoring normal blood flow and allowing drugs to reach their targets effectively.
The study explores various anti-angiogenic drugs, their mechanisms of action, and their potential to synergize with existing treatments like chemotherapy, targeted therapy, and immunotherapy.
“our findings demonstrate that angiogenesis is a central driver of drug resistance in breast cancer,” Dr. Mou emphasizes. “By targeting these abnormal blood vessels,we can enhance the potency of existing treatments,offering a more effective strategy to combat this disease and ultimately improve patient survival.”
This research offers hope for millions battling breast cancer. Incorporating anti-angiogenic therapies into treatment plans could lead to personalized treatment,reduce drug resistance,and ultimately improve survival rates and quality of life for patients worldwide.